Complera (Emtricitabine/Rilpivirine/Tenofovir disoproxil fumarate) for HIV

Overview
Complera is a prescription drug approved by the Food and Drug Administration (FDA) as a complete treatment regimen for HIV-1 infection in adults. Complera is a combination drug composed of Emtricitabine, Rilpivirine, and Tenofovir alafenamide fumarate, which are also known respectively by the abbreviations FTC, RPV, and TAF.

Rilpivirine is an antiviral medication of the non-nucleoside reverse transcriptase inhibitor (NNRTI) class. Emtricitabine and Tenofovir disoproxil fumarate are both antiretroviral medications of the nucleoside reverse transcriptase inhibitor (NRTI) class. All three drugs are believed to work by preventing HIV from replicating in cells.

How do I take it?
Prescribing information states that Complera is taken once daily. Complera comes in tablet form.

Side effects
The FDA-approved label for Complera lists common side effects including headache, fatigue, dizziness, depression, insomnia, unusual dreams, rash, nausea, and diarrhea. Rare but serious side effects listed for Complera include severe hypersensitivity reactions, lactic acidosis (a metabolic disorder), hepatomegaly (enlarged liver) with steatosis (fatty degeneration), severe exacerbation of Hepatitis B, kidney and liver problems, and a decrease in bone mineral density.

For more details about this treatment, visit:

Complera highlights of prescribing information – Gilead

Overview of HIV Treatments – AIDS.gov